1-3 of 3
A. Giza
Close
Sort by
Journal Articles

90 Y-Zevalin® ( 90 Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) Consolidation of FCM Induction Chemotherapy in Mantle Cell Lymphoma (MCL) Patients: Results from the PLRG upon Completed Enrollment.

Wojciech Jurczak, A. Giza, M. Szostek, A. Hubalewska-Dydejczyk, A. Sowa-Staszczak, W. Knopinska-Posluszny, A. Hellmann, B. Zdziarska, T. Wrobel, S. Krycz-Krzemien, L. Poplawska, I. Federowicz, Jan Walewski, Aleksander Skotnicki
Journal: Blood
Blood (2006) 108 (11): 2747.
https://doi.org/10.1182/blood.V108.11.2747.2747
Published: 2006
Journal Articles

Consolidation of Chemotherapy Response in Mantle Cell Lymphoma (MCL) Patients with 90 Y-Ibritumomab Tiuxetan ( 90 Y-Zevalin) Radioimmunotherapy (RIT).

W. Jurczak, A. Giza, D. Krochmalczyk, J. Wegrzyn, A. Hubalewska-Dydejczyk, A. Sowa-Staszczak, W. Knopinska-Posluszny, B. Zdziarska, S. Krycz-Krzemien, P. Boguradzki, L. Poplawska, A. Skotnicki
Journal: Blood
Blood (2005) 106 (11): 2453.
https://doi.org/10.1182/blood.V106.11.2453.2453
Published: 2005
Journal Articles

Manageable and Transient Hematologic Toxicity Associated with 90 Y-Ibritumomab Tiuxetan ( 90 Y-Zevalin) Consolidation of FCM Chemotherapy in Mantle Cell Lymphoma (MCL) Patients.

W. Jurczak, M. Szostek, A. Giza, Z. Rudzki, A. Skotnicki
Journal: Blood
Blood (2005) 106 (11): 4793.
https://doi.org/10.1182/blood.V106.11.4793.4793
Published: 2005